
Amgen (AMGN) Stock Forecast & Price Target
Amgen (AMGN) Analyst Ratings
Bulls say
Amgen's financial outlook is bolstered by a significant 40% increase in sales in the third quarter of 2025 compared to the same period in the previous year, with 16 products experiencing double-digit growth, including notable contributions from Repatha and Tezspire. The company's recent guidance increase for FY25 revenue to a range of $35.8 billion to $36.6 billion underscores its robust performance across established franchises and the anticipated strong ramp-up of Uplizna due to label expansions. Furthermore, projections indicate worldwide Uplizna sales could surge to $1.4 billion by 2027, reflecting the positive momentum in Amgen's portfolio and its strategic growth initiatives.
Bears say
Amgen is projected to experience minimal total revenue growth of approximately 1% in 2026 compared to 2025, primarily due to anticipated significant sales declines of around 28% for Prolia and 39% for Xgeva. Management has indicated that research and development spending growth will be muted, which raises concerns regarding the company's ability to invest adequately in its pipeline to sustain future growth. Although emerging products like MariTide and olpasiran exhibit clinical potential, there is limited visibility on their ability to compensate for the anticipated base business erosion resulting from the loss of exclusivity for key franchises.
This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.
Amgen (AMGN) Analyst Forecast & Price Prediction
Start investing in Amgen (AMGN)
Order type
Buy in
Order amount
Est. shares
0 shares